EGFR T790M: A Gatekeeper Resistance Mutation
T790M is a substitution at the 'gatekeeper' position of the EGFR kinase domain. In some EGFR-mutant lung cancers it appears after an earlier EGFR-directed therapy and changes the interaction between the kinase and a drug. The key interpretive challenge is that progression can be biologically mixed: T790M may be present in one clone while other resistance mechanisms or non-EGFR changes are also contributing.
Quick Answer
T790M is a substitution at the 'gatekeeper' position of the EGFR kinase domain. In some EGFR-mutant lung cancers it appears after an earlier EGFR-directed therapy and changes the interaction between the kinase and a drug. The key interpretive challenge is that progression can be biologically mixed: T790M may be present in one clone while other resistance mechanisms or non-EGFR changes are also contributing.
Why T790M Is Called a Gatekeeper Mutation
T790 sits at a position that helps control access to the EGFR ATP-binding pocket. The T790M substitution replaces threonine with methionine and can increase ATP affinity while creating steric and conformational obstacles for some earlier inhibitors. The result is a change in drug sensitivity, not a new cancer diagnosis or proof that every tumour cell has the variant.
T790M is most often discussed alongside an original sensitising alteration such as exon 19 deletion or L858R. A laboratory may report both variants, only one, or a changing mixture over time. Reading the result requires the treatment history and the assay's limit of detection.
When and How Resistance Testing Is Considered
When an EGFR-mutant tumour progresses, clinicians may consider a new tissue biopsy, plasma circulating-tumour-DNA test, or both. Tissue can reveal histologic transformation and broader pathology; plasma can provide a less invasive view of shed tumour DNA. Neither sample captures every resistant clone, so a non-detected result should be interpreted with the clinical and radiographic context.
A robust report identifies whether T790M was detected, the specimen and assay used, the variant allele fraction when available, and any quality or coverage limitations. If a result conflicts with the disease course, the next step is a multidisciplinary review rather than an automatic conclusion that the test or the patient is 'wrong'.
Reading the FDA Label Carefully
The FDA prescribing information linked below describes osimertinib for metastatic EGFR T790M-positive NSCLC in patients whose disease has progressed on or after an EGFR tyrosine-kinase inhibitor. The label is the authoritative boundary for that statement. It should not be paraphrased as a recommendation for every progression event, every EGFR variant, or every stage of disease.
Resistance is often heterogeneous. MET amplification, other EGFR substitutions such as C797S, KRAS or BRAF pathway changes, and small-cell transformation are examples of mechanisms that can coexist with or replace T790M. This is why a molecular result is best used to frame a clinician-led discussion about the next diagnostic and treatment question.
Key Takeaways
- ·T790M changes the EGFR kinase gatekeeper position and can reduce sensitivity to some earlier EGFR inhibitors.
- ·The result is most meaningful alongside the original EGFR alteration, treatment history, specimen, and assay limitations.
- ·The FDA label cited here is specific to metastatic T790M-positive NSCLC after progression on or after an EGFR TKI.
- ·A negative liquid-biopsy result does not automatically rule out a resistant clone, and progression can have more than one mechanism.
Put these genes in pathway context
Frequently asked questions
What is the key idea in EGFR T790M: A Gatekeeper Resistance Mutation?
T790M is a substitution at the 'gatekeeper' position of the EGFR kinase domain. In some EGFR-mutant lung cancers it appears after an earlier EGFR-directed therapy and changes the interaction between the kinase and a drug. The key interpretive challenge is that progression can be biologically mixed: T790M may be present in one clone while other resistance mechanisms or non-EGFR changes are also contributing.
What should be kept with the result or mechanism?
The result is most meaningful alongside the original EGFR alteration, treatment history, specimen, and assay limitations. The FDA label cited here is specific to metastatic T790M-positive NSCLC after progression on or after an EGFR TKI. A negative liquid-biopsy result does not automatically rule out a resistant clone, and progression can have more than one mechanism.
References
Continue Reading
EGFR Exon 19 Deletions: What the Biomarker Means
4 min read
EGFR L858R: Understanding the Exon 21 Mutation
3 min read
EGFR Mutations in NSCLC: Testing, Inhibitors and Resistance
5 min read
KRAS Mutations: Constitutive MAPK Signalling and Targeted Therapy
6 min read
EGFR C797S: What This Resistance Alteration Means
2 min read
MET Amplification in EGFR-Mutant Cancer: A Resistance Mechanism
2 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
EGFR has 1000+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.